Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2017 - 07 - 31
点击次数: 0
Positions: President
Company: Hinova Pharmaceuticals Inc.
个人简介:
陈元伟博士,美籍华人,瑞士洛桑大学博士,美国Scripps研究所博士后。国家千人计划特聘专家,成都海创药业有限公司创始人和总经理,四川大学特聘教授,四川省千人计划,成都市人才计划特聘专家,2012年度成都市十佳科技创新人才。先后担任美国拜耳(Bayer)制药资深科学家和项目管理人,安全委员会主席;美国雅培(Abbott Lab)制药公司高级科学家;白鹭医药技术(上海)首席科技官和创始科学家。上海睿智化学药物化学副总裁,成都睿智化学总经理等职务。主要研究方向是重大疾病如癌症,糖尿病,心血管疾病创新药物研究和产业化。 陈元伟博士具有22年国内外著名制药公司药物研发和管理经验,在中国和美国共领导和参与了20多种新药项目的研究,其中5种正在进行临床I,Ⅱ期试验,1种(糖尿病新药)在美国进行Ⅲ期临床研究。共申请了一类新药相关的各项专利80项,已经授权30项,发表论文50余篇。其中包括了糖尿病药SGLT2抑制剂的核心专利(US7,838,499; US7,803,778), 治疗流行性感冒核心专利(US6,518,305),癌症新药研究核心专利(US6,849,638)。
发布时间: 2017 - 07 - 31
点击次数: 0
Positions: Co-founder and President
Company: Connect Biopharmaceuticals, Ltd.
个人简介:
Dr. Pan has 20 years experiences in bioscience in North America and China, with extensive experiences in new drug R&D, as well as management, operation and fund raising. He joined TsingHua YuanXing Biopharmaceutical Co. Ltd. in 2000 as vice president and co-founded and served as VPs and general manager for a couple of biotech companies, where he played key role for the development of several gene-based biologics and was involved in the development and successfully marketing of a few biomedical products. In 2006, Dr. Pan co-founded Crown Bioscience, Inc., a leading CRO in oncology drug discovery where he worked as Chief Operation Officer, Executive Vice President and the President of Greater China. In 2012, he co-founded Connect Biopharmaceuticals, Ltd., an immune-modulator drug R&D Biotech successfully moved a few programs into clinical research by leveraging high quality support from multiple CROs. Dr. Pan obtained his Ph.D. in Biology in Sussex University (UK) and worked as a postdoctoral researcher at University of California at Berkeley.
发布时间: 2017 - 07 - 31
点击次数: 0
Positions: General Manager
Company: DOER Biologics
个人简介:
Huang got M.D at Zhejiang Universtiy and has more than 20 years experiences on biopharmaceuticals. He had been as CSO in Hangzhou Jiuyuan Gene Engineering co., LTD, during which he was responsible for getting two biosimilar market licenses (include the first G-CSF in China) and a clinic trial permission license for an innovative recombinant protein drug. Since 2008, Dr. Huang was a co-founder of T-mab Biopharma and responsible for the development of T-mab’s therapeutic antibody and protein projects. In T-Mab, he had set up two technology platforms -- the long-acting recombinant protein drugs and therapeutic monoclonal antibodies, and developed 3 innovative biological drugs and 1 biosimilars with 30M RMB shareholder investment, and all are in clinical trials in China. In 2015, T-Mab was acquired by a domestic big pharma in near 300M RMB. After that, Dr. Huang found Doer Biologics in Hangzhou in 2015, which focus in developing “biobetter”and "best-in-class" biodrugs with creative long-acting biodrug platform and innovative multi-domain technology.
发布时间: 2017 - 08 - 02
点击次数: 0
Positions: Board Chairman and CEO
Company: QIAGEN (Suzhou) Translational Medicine Co. Ltd.
个人简介:
With over 25 years of drug R&D experience and years of experience in translational and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co. Ltd. that provides an integrated technology platform for biomarker, companion diagnostics development and clinical testing for precision medicine.  Nick was China GM and Corporate SVP for Frontage Lab, a CRO for CMC, Clinical and Bioanalytical services. Before that, Nick was a founding director and executive for Novartis China R&D center and responsible for building up CPP/TRD division in China. He also served on the cFDA Working Committee and as a reviewer for China Thousand Talents Program. Prior to Novartis, Nick was a director at US OSI Pharmaceuticals. Nick started his drug industry career at Pfizer global R&D center after he got his Ph.D degree from University of Cincinnati. During his ten years at Pfizer, he led teams at both Early and Full Development in Pharmaceutical Science, filed 5 INDs/IMPD and 1 NDA/MAA for various dosage forms. Nick represented Pfizer serving on the PRQI working committee (formed among FDA, industry and academia). Before going to US, Nick worked and studied at Chinese Academy of Sciences. Nick is now a member of Bayhelix, a global association of Chinese Life Science Business Executives; a council member of Jiangsu Life Science and Technology Association; and a director of Biomedical Committee (SEBMC), Sino-EU Chemical/Manufacturer Association.He is also one of the 2015 Suzhou SIP Leading Talents.